文献速递其他结缔组织病

系统性硬化症三抗体阴性患者的临床与血清学特征:意大利风湿病学会多中心SPRING登记研究

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.
PubMed 文献 · RMD Open · 2026-05-13

该研究基于意大利风湿病学会多中心SPRING登记中1480例系统性硬化症(SSc)患者,回顾性分析三抗体阴性(ATA、ACA、RNAP3均阴性)患者的流行率与临床特征。结果显示295例(19.9%)为三抗体阴性,该组肌病和间质性肺病更常见、血管并发症更少,提示其可能代表一种类似硬化性肌炎的内型。

要点

  • 三抗体阴性SSc占19.9%,肌病患病率更高(16.7% vs 10.1%)。
  • 三抗体阴性组间质性肺病更多,DLCO和FVC更低。
  • 三抗体阴性组指端溃疡和钙质沉着更少,血管并发症负担较低。

核心结论

  • 三抗体阴性SSc患者肌病和间质性肺病患病率更高、血管并发症负担更低,提示非特异性自身抗体可能识别出类似硬化性肌炎的SSc内型。

研究设计与样本

  • 基于意大利风湿病学会多中心SPRING登记(Systemic sclerosis Progression INvestiGation registry)的回顾性评估,共纳入1480例SSc患者,比较三抗体阴性组与SSc特异性抗体阳性组的临床特征。

主要发现

  • 1480例SSc中295例(19.9%)为三抗体阴性,1185例(81.1%)有SSc特异性抗体:ACA 54.3%、ATA 43.6%、RNAP3 2.1%。
  • 三抗体阴性组肌病患病率16.7% vs 10.1%(p=0.003),CPK水平126.2 vs 92.5 U/mL(p=0.002),CPK升高超过2-3倍者2.4% vs 0.2%(p=0.028)。
  • 三抗体阴性组指端溃疡17.3% vs 22.8%(p=0.04)、钙质沉着8.2% vs 12.8%(p=0.027)更少,间质性肺病患病率更高(p<0.001)。
  • 三抗体阴性组DLCO 66.4% vs 70.98%(p=0.004)、FVC 97.01% vs 102.92%(p<0.001)更低。
  • 三抗体阴性组更常用糖皮质激素(79.3% vs 67.9%,p=0.003)、环磷酰胺(43.4% vs 26%,p<0.001)和硫唑嘌呤(38.5% vs 22.3%,p=0.002),更少用前列环素类似物(71.6% vs 85.9%,p<0.001)、钙通道阻滞剂(80.1% vs 87.7%,p=0.005)和磷酸二酯酶-5抑制剂(4% vs 20%,p<0.001)。

关键数值与推荐

  • 2013年ACR/EULAR SSc分类标准纳入ATA、ACA和RNAP3三种自身抗体,符合标准但三者均阴性者归类为「三抗体阴性」。
  • 三抗体阴性组肌病16.7% vs 10.1%(p=0.003),CPK 126.2 vs 92.5 U/mL(p=0.002),CPK升高超过2-3倍2.4% vs 0.2%(p=0.028)。
  • 三抗体阴性组指端溃疡17.3% vs 22.8%(p=0.04),钙质沉着8.2% vs 12.8%(p=0.027),间质性肺病p<0.001。
  • 三抗体阴性组DLCO 66.4% vs 70.98%(p=0.004),FVC 97.01% vs 102.92%(p<0.001)。

临床怎么用

  • 对三抗体阴性SSc患者应加强肌病筛查(CPK监测)和间质性肺病评估(肺功能与影像)。
  • 三抗体阴性SSc患者血管并发症负担较低,血管靶向治疗的使用强度可能相应不同。
  • 三抗体阴性SSc患者更常接受糖皮质激素、环磷酰胺和硫唑嘌呤治疗,提示其治疗模式偏向炎症/肌病表型。

局限性

  • 本研究为回顾性评估,原文摘要未报告非特异性自身抗体检测范围及随访时长等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antitopoisomerase I (ATA), anticentromere (ACA) and anti-RNA polymerase III (RNAP3) antibodies are included in the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for systemic sclerosis (SSc). A subset of patients with SSc satisfy criteria but may lack these specific autoantibodies, being classified as 'triple-negative'. METHODS: We conducted a retrospective evaluation of triple-negative patients with SSc prevalence and clinical features among the multicentric Systemic sclerosis Progression INvestiGation registry. RESULTS: Out of 1480 patients with SSc, 295 (19.9%) were triple-negative, while 1185 (81.1%) had SSc-specific antibodies: ACA (54.3%), ATA (43.6%) and RNAP3 (2.1%). The triple-negative group showed a higher prevalence of myopathy (16.7% vs 10.1%, p=0.003), suggested by higher creatine phosphokinase (CPK) levels (126.2 vs 92.5 U/mL, p=0.002), more frequent CPK increase over 2-3 times (2.4% vs 0.2%, p=0.028). Triple-negative patients also exhibited fewer vascular complications, including digital ulcers (17.3% vs 22.8%, p=0.04) and calcinosis (8.2% vs 12.8%, p=0.027), and a higher prevalence of interstitial lung disease (p<0.001). Consistently, lower diffusing capacity for carbon monoxide (66.4% vs 70.98%, p=0.004) and forced vital capacity (97.01% vs 102.92%, p<0.001) were found in the triple-negative group. Triple-negative patients more frequently received corticosteroids (79.3% vs 67.9%, p=0.003), cyclophosphamide (43.4% vs 26%, p<0.001) and azathioprine (38.5% vs 22.3%, p=0.002), while less frequently received prostanoids (71.6% vs 85.9%, p<0.001), calcium channel blockers (80.1% vs 87.7%, p=0.005) and phosphodiesterase-5 inhibitors (4% vs 20%, p<0.001). CONCLUSIONS: A higher prevalence of myopathy and interstitial lung disease and a reduced vascular burden were found in the triple-negative patients, suggesting that the non-specific and non-routinely tested autoantibodies may identify an SSc endotype resembling sclero-myositis.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Batani V, Cavazzana I, Orlandi M, et al. Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology. RMD Open. 2026. PMID: 42128529. doi:10.1136/rmdopen-2025-006495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。